1. Home
  2. NCMI vs BCYC Comparison

NCMI vs BCYC Comparison

Compare NCMI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.40

Market Cap

306.0M

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$5.04

Market Cap

360.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
BCYC
Founded
2005
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
360.7M
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
NCMI
BCYC
Price
$3.40
$5.04
Analyst Decision
Buy
Buy
Analyst Count
4
10
Target Price
$5.63
$13.90
AVG Volume (30 Days)
399.0K
574.3K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
3.55%
N/A
EPS Growth
52.17
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.20
N/A
Revenue Next Year
$6.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.92
$4.24
52 Week High
$6.18
$9.55

Technical Indicators

Market Signals
Indicator
NCMI
BCYC
Relative Strength Index (RSI) 55.96 52.54
Support Level $3.17 $5.03
Resistance Level $3.90 $5.90
Average True Range (ATR) 0.14 0.25
MACD 0.04 0.09
Stochastic Oscillator 85.71 90.50

Price Performance

Historical Comparison
NCMI
BCYC

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: